Overview

forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The study purpose is to assess adverse events in patients with Type 2 diabetes who have newly been prescribed Forxiga for the management of glycemic control
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Monash University
Treatments:
Dapagliflozin